Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384770 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL18416922 | 0.88 | — | — | |
| SCHEMBL18416928 | 0.81 | CNR2 (0.30) | — | |
| SCHEMBL18202958 | 0.79 | OPRD1 (0.36) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL18590288 | 0.78 | CYP3A4 (0.31) | — | |
| SCHEMBL18199671 | 0.78 | — | — | |
| SCHEMBL18199651 | 0.77 | TSHR (0.40) | — | |
| SCHEMBL18155874 | 0.76 | OPRM1 (0.32) | OPRM1OPRD1OPRK1JAK1 | |
| SCHEMBL18199656 | 0.76 | OPRM1 (0.30) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19323250 | 0.74 | OPRM1 (0.34) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-9850251-B2 | Imidazole derivative used as antiviral agent and use therof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-9850251-B2 | Imidazole derivative used as antiviral agent and use therof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | SHANGHAI JIA TAN PHARMATECH CO. LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | MTOR, PIK3CA, PIK3CD | OPRM1 4231/4885OPRD1 3140/4885OPRK1 2494/4885 |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | DDT, CYP3A43, CYP19A1 | OPRM1 2449/4885OPRD1 3067/4885OPRK1 2499/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | OPRM1 3097/4885OPRD1 1498/4885OPRK1 2623/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | OPRM1 1641/4885OPRD1 2525/4885OPRK1 1920/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | OPRM1 3295/4885OPRD1 2121/4885OPRK1 1519/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | OPRM1 4096/4885OPRD1 2841/4885OPRK1 1815/4885 |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | MAVS, SARS1, IRF3 | OPRM1 4400/4885OPRD1 3941/4885OPRK1 4198/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | OPRM1 3669/4885OPRD1 1607/4885OPRK1 2853/4885 |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | ME3, SSBP1, MDH2 | OPRM1 2649/4885OPRD1 2786/4885OPRK1 2903/4885 |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | DDT, CYP3A43, CYP19A1 | OPRM1 2449/4885OPRD1 3067/4885OPRK1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.